WAYNE, PA — XyloCor Therapeutics, Inc. recently revealed the final results from the Phase 2 segment of its EXACT clinical trial at the Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions. The study focused on XC001 (encoberminogene rezmadenovec), XyloCor’s leading gene therapy candidate for refractory angina, a condition that affects over one million Americans and is on the rise.
Refractory angina, characterized by chronic chest pain due to reduced blood flow to the heart, often leaves patients with limited treatment options. XC001 aims to alleviate this issue by employing a one-time gene therapy to promote the creation of new blood vessels in the heart, a process facilitated through the expression of vascular endothelial growth factor (VEGF) isoforms.
The Phase 2 trial’s promising outcomes, which will also be published in Circulation: Cardiovascular Interventions, demonstrate XC001’s potential not only to improve cardiovascular health but also to enhance the quality of life for those suffering from this debilitating condition. Administered through a minimally invasive procedure directly to the heart, the therapy was tested on 32 patients experiencing class II-IV angina.
Notably, the treatment has shown to be safe and effective, yielding durable clinical improvements such as extended exercise duration, decreased ischemic burden verified by PET imaging, and a significant reduction in angina frequency. Six months post-treatment, an impressive 43% of participants reported no chest pain during everyday activities—a drastic improvement from their severe limitations prior to receiving XC001.
These findings, underscored by the absence of serious adverse events related to the gene therapy, highlight the potential of XC001 to serve as a groundbreaking alternative for individuals lacking viable treatment routes for refractory angina.
Al Gianchetti, President and CEO of XyloCor, expressed optimism regarding the trial’s results, emphasizing the company’s commitment to advancing XC001 through further clinical trials. This next step could potentially confirm the gene therapy as a crucial addition to cardiac care, offering hope to patients and families affected by refractory angina and marking a pivotal moment in cardiovascular disease management.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.